BELLEVUE, Wash., March 14,
2023 /PRNewswire/ -- Bellevue Life Sciences
Acquisition Corp. (the "Company") announced that holders of the
6,900,000 units sold in the Company's initial public offering,
including the 900,000 units sold pursuant to the full exercise of
the underwriters' over-allotment option, may elect to separately
trade the shares of common stock, warrants and rights included in
the units commencing March 17, 2023.
Any units not separated will continue to trade on The Nasdaq
Capital Market ("Nasdaq") under the ticker symbol "BLACU," and the
separated shares of common stock, warrants and rights will trade on
the Nasdaq under the ticker symbols "BLAC," "BLACW" and "BLACR,"
respectively. Holders of units will need to have their brokers
contact Continental Stock Transfer & Trust Company, the
Company's transfer agent, in order to separate the units into
shares of common stock, warrants and rights.
The units were initially offered by the Company in an
underwritten offering. Chardan acted as sole book-running manager
of the offering.
A registration statement relating to the units and the
underlying securities was declared effective by the U.S. Securities
and Exchange Commission (the "SEC") on February 9, 2023. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Bellevue Life Sciences Acquisition Corp.
The
Company is a blank check company whose business purpose is to
effect a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or similar business combination with one
or more businesses. While the Company will not be limited to a
particular industry or geographic region in its identification and
acquisition of a target company, the Company intends to focus our
search on companies in the healthcare industry.
Forward Looking Statements
This press release contains
statements that constitute "forward-looking statements," including
with respect to the anticipated separation of the units into shares
of common stock, warrants and rights. No assurance can be given
that the units will be separated as indicated. Forward-looking
statements are subject to numerous conditions, many of which are
beyond the control of the Company, including those set forth in the
Risk Factors section of the Company's registration statement and
final prospectus relating to the Company's initial public offering
filed with the SEC. Copies are available on the SEC's website,
www.sec.gov. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Contact:
Tom Shin,
Senior Vice President and Corporate Secretary
Phone: +1 (206) 317-9114, Email: tom.shin@bellevuecm.com
View original
content:https://www.prnewswire.com/news-releases/bellevue-life-sciences-acquisition-corp-announces-separate-trading-of-its-shares-of-common-stock-warrants-and-rights-commencing-march-17-2023-301772041.html
SOURCE Bellevue Life Sciences Acquisition Corp.